NORYVA
Retatrutide
Body goals: the most advanced human data in the range.
10 mg
This is the most explored reference for weight loss and appetite control. Published trials measured it in real people, followed for several months.
- Less hunger day to day.
- Fullness that lasts longer.
- Smaller portions, without thinking about it.
What is being looked at?
- Weight loss
- Body shape
- Appetite control
- Satiety
- Control over eating
- Metabolism
- Blood sugar
- Digestion
The essentials
- Format
- 10 mg
- Storage · Batch number · Manufactured · Expiry · Batch purity
- On the batch certificate
- Evidence level
- Clinical data
- Use
- For research and laboratory use only.
The question you are asking yourself
Everyone promises weight loss. Why believe you?
Because we promise nothing. Published phase 2 trials measured, in people followed for several months, substantial weight loss and reduced hunger. “Phase 2” means measured, not finished — and that is exactly what we write.
Why this reference?
It is the most advanced reference in the range on the human-data side. Published trials measured, in people followed for several months, substantial weight loss, less hunger and smaller amounts eaten. These are phase 2 trials: real measurements on real people, but not a completed file.
What you should know
Scientific detail
What it is
Retatrutide is a synthetic peptide designed to act on three receptors at once: GIP, GLP-1 and the glucagon receptor. It appears in the literature under the code LY3437943.
Why it is studied
All three receptors take part in metabolic regulation. Acting on the three together rather than on one is precisely what this molecule is used to study.
Described mechanism
Proposed mechanism: simultaneous agonism of the GIP, GLP-1 and glucagon receptors. What acting on three pathways at once produces cannot be deduced from what each does separately.
What the research has studied
- Metabolism
- Blood sugar regulation
- Gut hormones
Human data
The phase 2 trials are published, and they measured. In the trial published in the New England Journal of Medicine in 2023, mean weight change reached −17.5% at 24 weeks and −24.2% at 48 weeks on the 12 mg dose, against −2.1% on placebo. A separate phase 2 analysis reports reduced overall appetite, less hunger and lower daily calorie intake than placebo from the first month. These results concern specific endpoints, in specific populations, over specific durations, under medical supervision and at protocol-defined doses: they transfer neither to other endpoints, nor to other people, nor to use outside that setting.
Preclinical data
Published preclinical work on the molecule's affinity and activity at the three receptors.
What the data does not say
Investigational molecule. No marketing authorisation, in any country. Clinical development is not complete, and a phase 2 result is not a conclusion. The long-term tolerability profile is not established.
Regulatory status
For laboratory research purposes only. Not for human consumption or therapeutic use.
This reference holds no marketing authorisation as a medicinal product.
Customer reviews
Frequently asked questions
Can I order Retatrutide today?
No. This reference is not offered for sale: its commercial framework is not settled. No purchase button is shown until it is.
Does Retatrutide hold a marketing authorisation?
No. This reference holds no marketing authorisation as a medicinal product and is approved by no authority for human use. A publication or a clinical trial never amounts to approval.
What analyses are available?
The certificate of analysis is supplied with the batch delivered. No batch number or purity figure is published until the real certificate has been entered: we do not display illustrative values.
How is this reference stored?
The storage requirement is not yet on file: the supplier data sheet has not reached us. We would rather say so than assume.
Is it compatible with the NORYVA injector pen?
Compatibility is not confirmed for this reference. Until the manufacturer confirms it, we do not claim it.
What does the available data actually show?
Investigational molecule. No marketing authorisation, in any country. Clinical development is not complete, and a phase 2 result is not a conclusion. The long-term tolerability profile is not established.
Work out a volume
The vial amount is prefilled from this page. The solvent volume and the amount aimed for are yours to enter: NORYVA proposes neither.